This Week in Pediatric Oncology

This Week in Pediatric Oncology header image 1

Entries Tagged as 'children'

TWiPo #59 ~ Interview with Dr. Sajid Qureshi

October 17th, 2016 · Comments

Host Dr. Timothy Cripe and co-Host Nilay Shah interview Dr. Sajid Qureshi, a professor of Pediatric Oncology at the Tata Memorial Center, Mumbai, India. Dr. Qureshi is an Executive Committee Member of the International Society of Pediatric Surgical Oncology (IPSO). In this episode Dr. Qureshi provides a fascinating, first-hand glimpse into the successes and challenges of delivering quality care to larger, as well as remote, pediatric cancer populations. The episode concludes with Dr. Qureshi's thoughts on how international research collaboration could provide access to relapsed children worldwide.


Tags: families · cancer · children · pediatric cancer · childhood cancer · drug development · neuroblastoma · research · brain tumor · clinical trials · Advancement in Cancer Research

TWiPO #58 ~ Interview with Dr. Damon Reed

October 17th, 2016 · Comments

TWiPO Host Dr. Timothy Cripe, with co-hosts Dr. Nilay Shah and Dr. Bhuvana Setty welcome Dr. Damon Reed, Director of the Adolescent and Young Adult Program at Moffitt Cancer Center and Leader of the Pediatric Cancer Foundation's pediatric phase I consortium, the Sunshine Project. Dr. Reed shares his view points on how we can improve and accelerate the current trajectory with regard to pediatric therapy development. 


Tags: families · cancer risk · cancer · children · pediatric cancer · childhood cancer · drug development · neuroblastoma · medulloblastoma · sarcoma · research · brain tumor · immunotherapy · clinical trials · Advancement in Cancer Research

TWIPO # 57 Interview with Dr. Elizabeth Lawlor

October 6th, 2016 · Comments

TWIPO hosts Dr. Timothy Cripe and Dr. Nilay Shah (Nationwide Children's Hospital) along with guest host Dr. Ryan Roberts (Nationwide Children's Hospital), interview Dr. Elizabeth Lawlor who is a Professor of Pediatric Oncology at University of Michigan and the Director of the Cancer Biology Training Program at University of Michigan Health System. Dr. Lawlor, a Ewing Sarcoma specialist, discusses new approaches to the cellular eco-system of tumors and provides commentary on the growing landscape for women in science.


Tags: cancer · children · pediatric cancer · childhood cancer · sarcoma · research · immunotherapy · young adults · Ewing Sarcoma · Epigenetics

TWIPO #56 ~ Interview with Dr. Mark Hatley

September 6th, 2016 · Comments

On today's podcast, TWIPO host Dr. Timothy Cripe (Nationwide Children’s Hospital) and co-host Dr. Ryan Roberts (Nationwide Children’s Hospital) interview Dr. Mark Hatley (St. Jude Children's Research Hospital). Dr. Hatley discusses how he got into the field of Biological Chemistry in Oncology. Also Dr. Hatley gives an indepth explaination about his research in G-Proteins.


Tags: cancer · children · pediatric cancer · childhood cancer · drug development · neuroblastoma · medulloblastoma · research · brain tumor · immunotherapy · clinical trials · Advancement in Cancer Research

TWiPO #55 ~ Interview with Dr. Chrystal Louis

June 3rd, 2016 · Comments

On this episode of TWiPO podcast Dr. Timothy Cripe (Nationwide Children’s Hospital) and co-host, Dr. Nilay Shah (Nationwide Children’s Hospital) and Dr. Keri A. Streby (Nationwide Children's Hospital) interview Dr. Chrystal Louis (Assistant Professor, Department of Pediatrics, Section of Hematology-Oncology, Baylor College of Medicine.) Dr. Louis talks to the hosts about her role in both the academic and industry side of oncology. 


Tags: cancer · children · pediatric cancer · childhood cancer · drug development · research · brain tumor · clinical trials · Advancement in Cancer Research

TWiPO #54 ~ Interview with Dr. Kim Kramer

June 3rd, 2016 · Comments

On today's TWiPO Podcast host Dr. Timothy Cripe (Nationwide Children’s Hospital) and co-host, Dr. Nilay Shah (Nationwide Children’s Hospital) interview Dr. Kim Kramer (Pediatric Oncologist of Memorial Sloan Kettering.) In this interview they discuss a new cutting edge therapy for treating brain tumors, which involves targeting the tumor intravenously just like any other tumor.


Tags: families · cancer · children · pediatric cancer · childhood cancer · drug development · brain tumor

TWiPO #53 ~ Interview with Linda McAllister-Lucas

April 13th, 2016 · Comments

On today's podcast TWiPO host Dr. Timothy Cripe (Nationwide Children’s Hospital) and co-hosts, Dr. Nilay Shah (Nationwide Children’s Hospital) and Dr. Robyn Dennis (Nationwide Children’s Hospital) Interview Dr. Linda McAllister-Lucas (Chief of Service, Hematology/Oncology of Children's Hospital of Pittsburgh, Associate Professor of Pediatrics, University of Pittsburgh School of Medicine. In their discussion Dr. McAllister-Lucas talks about her research on MALT1 Lymphoma and how this research could advance the field of oncology 


Tags: cancer risk · cancer · children · pediatric cancer · childhood cancer · drug development · research · brain tumor · Advancement in Cancer Research

TWIPO #52 ~ Interview with Dr. James Geller

December 9th, 2015 · Comments

On this TWiPO episode hosts, Dr. Timothy Cripe and Dr. Nilay Shah (Nationwide Children’s Hospital) interview Dr. James Geller (Medical Director at Kidney and Liver Tumors Program, Co-Medical Director at Retinoblastoma Program, Associate Director at Global Cancer Programs, Associate Professor at UC Department of Pediatrics.) Dr. James Geller was one of the original TWiPO members back in 2010. Today Dr. Geller talks about the battle to get access to potential drugs (Ex. Lorvotuzumab [IMGN901]) that can be beneficial to treating pediatric cancers.


Tags: cancer · children · pediatric cancer · childhood cancer · drug development · neuroblastoma

TWIPO #49 ~ Interview With Dr. Robin Norris

April 20th, 2015 · Comments

TWiPO host Dr. Timothy Cripe (Nationwide Children’s Hospital) and TWiPO co-host Dr. Nilay Shah (Nationwide Children’s Hospital) interview Robin Norris, MD, who is a pediatric oncologist and the Director of the Pediatric Developmental Therapeutics Program, Division of Pediatric Hematology and Oncology, at University Hospitals Rainbow Babies & Children's Hospital. Dr. Norris discusses the struggles that adolescents and young adult with cancer face and discusses her involvement in creating an antibody against TEM-1 in order to stop the metastasis of tumors.


Tags: children · pediatric cancer · young adults

TWIPO #34 ~Interview With Dr. Nancy Ratner

February 10th, 2014 · Comments

November 14, 2013

New York, NY -- This Week in Pediatric Oncology (TWiPO), the first podcast focusing on pediatric cancer research, announced that Nancy Ratner, PhD, is a featured guest on its most recent episode, In this episode, Dr. Ratner speaks with host Dr. Tim Cripe (Nationwide Children's Hospital) and co-host Dr. Robyn Dennis (Nationwide Children's Hospital).

Dr. Ratner is interested in understanding mechanisms of peripheral nerve tumor (neurofibroma) formation in Neurofibromatosis type 1 (NF1), a common inherited disorder in which children are predisposed to cancer of the nervous system, to learning problems, bone disorders, and other cancers. She identified EGFR as a potential therapeutic target in NF1 peripheral nerve tumorigenesis, and has developed cell culture and mouse models of NF1 nerve tumorigenesis. Her laboratory has also used analysis of gene expression to identify critical genes in neurofibroma and their malignant derivatives, MPNST.

Dr. Ratner is currently a professor in the Department of Pediatrics, Cincinnati Children’s Hospital, University of Cincinnati, and the program leader for Cancer Biology and Neural Tumors Program in the Cancer and Blood Disorders Institute where she holds the Beatrice C. Lampkin Endowed Chair in Cancer Biology and serves as PI of the NINDS P50 “Cincinnati Center in NF Research.”


Tags: children · neurofibroma

TWIPO #31 ~ Secondary Cancers in Childhood Cancer Survivors

February 10th, 2014 · Comments

October 03, 2013

Dr. Joseph Neglia (University of Minnesota) is nationally and internationally recognized for his contributions to the field of childhood cancer long-term effects. He is the featured guest in this week's podcast episode, and answers questions from host Dr. Tim Cripe (Nationwide Children’s Hospital), and co-hosts Dr. Robyn Dennis (Nationwide Children’s Hospital), Dr. Andy Kolb (AI DuPont), and Donna Ludwinski (Solving Kids’ Cancer), about late effects and the risk of secondary cancers among childhood cancer survivors.


Tags: families · cancer risk · children · childhood cancer · late effects

TWiPO #24 ~ Cord Blood Banking: Interview with Machi Scaradavou

February 10th, 2014 · Comments

March 06, 2012

Dr. Tim Cripe welcomes Dr. Andy Kolb from AI DuPont in this episode of TWiPO, and special guest Dr. Andromachi Scaradavou, the Medical Director of New York Blood Center's National Cord Blood Program.

NYBC is the world's oldest and largest public cord blood bank, and collects, processes, tests and stores cord blood that mothers donate shortly after birth. The cord blood is for children and adults with no related donor available who need a hematopoietic stem cell transplant for life-threatening illnesses. More than 60,000 units are stored at NYBC and more than 4500 units have been provided for transplants worldwide. The variety of ethic groups represented is much higher in cord blood banking than in bone marrow donor programs. The percentage of use is climbing significantly for pediatric transplants partly because of the small dose required.

Discussants cover many aspects of this fascinating subject: background and uses of cord blood, logistics of collecting, processing, storing, and selecting units for transplants, as well as the advantages and challenges currently faced in this field. For more on NYBC see

We welcome all questions or comments at


Tags: children · cord blood banking

TWiPO #19 ~ More on Hedgehog signaling, brain tumor risk from cell phone use, and FDA approval of cancer drugs

February 10th, 2014 · Comments

October 30, 2011

Several just-published papers in the literature relate to recent podcast episodes, and host Dr. Tim Cripe and co-host Dr.  Lionel Chow review these interesting developments.

0:55 Hedgehog Signaling: Recent papers discussing this pathway in neuroblastoma and rhabdomyosarcoma are discussed, with implications for treatment in these tumor types with itraconozole.

6:40 Cell phone and brain tumor risk: The controversy concerning criticism by the Environmental Health Trust of a study showing that cell phone use does not increase risk of brain tumors in children is explored.

Accelerated approval of cancer drugs by the FDA and implications for pediatric cancers.

15:30 Brentuximab for two types of lymphoma

21:20 Vemurafenib for melanoma

28:30 Crizotinib for non-small cell lung cancer (and potential use in neuroblastoma)

42:30 Response to email regarding personalized medicine TWiPO episode #17 and lab blog for Dr Charles Keller at OHSU


Pediatr Blood Cancer. 2011 Dec 1;57(6):930-8. doi: 10.1002/pbc.23174. Hedgehog pathway activity in pediatric embryonal rhabdomyosarcoma and undifferentiated sarcoma: a report from the Children's Oncology Group.

Int J Oncol. 2011 Oct;39(4):899-906. doi: 10.3892/ijo.2011.1076. Pharmacological inhibition of the Hedgehog pathway preventshuman rhabdomyosarcoma cell growth.

Cancer Lett. 2011 Nov 28;310(2):222-31. Inhibition of the sonic hedgehog pathway by cyplopaminereduces the CD133+/CD15+ cell compartment and the in vitrotumorigenic capability of neuroblastoma cells.

Cell Phone Study Was Flawed, Say Some Experts by Roxanne Nelson Medscape Oncology News.

The JNCI Study by Aydin et al on Risk of Childhood Brain Cancer from Cellphone Use Reveals Serious Health Problems, Environmental Health Trust.

N Engl J Med. 2010 Nov 4;363(19):1812-21. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas.

FDA Approves Brentuximab for Two Lymphomas By: ELIZABETH MECHCATIE, Oncology Report Digital Network.

Clin Cancer Res. 2011 Oct 15;17(20):6428-36. Brentuximab Vedotin (SGN-35).

FDA Approves Vemurafenib for Advanced Melanoma. By: JANE SALODOF MACNEIL, Oncology Report Digital Network.

N Engl J Med. 2011 Jun 30;364(26):2507-16. Improved survival with vemurafenib in melanoma with BRAFV600E mutation.

N Engl J Med. 2011 Jun 30;364(26):2547-8. Been there, not done that--melanoma in the age of molecular therapy.

Biochem J. 2011 Aug 15. Activating ALK mutations found in neuroblastoma are inhibited by Crizotinib and NVP-TAE684.

N Engl J Med. 2010 Oct 28;363(18):1693-703. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

Nature. 2007 Aug 2;448(7153):561-6. Epub 2007 Jul 11. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.

Science. 1994 Mar 4;263(5151):1281-4. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma.


Tags: children · childhood cancer · neuroblastoma · sarcoma

TWiPO #18 ~ Targeting EWS-FLI1 in Ewing’s Sarcoma: Interview with Dr Jeff Toretsky

February 10th, 2014 · Comments

October 18, 2011

Host Dr. Tim Cripe and co-host Dr. Lionel Chow welcome special guest Dr. Jeff Toretsky on TWiPO to discuss his clinical and research interest in Ewing's sarcoma. Dr. Toretsky explains the challenges of developing a clinical grade drug from a small molecule for a specific target such as EWS-FLI1. The small market for a disease like Ewing's creates formidable hurdles for researchers, yet Dr. Toretsky is driven on by the question "If I don't do this, who will?" (17:54 mins)

Dr. Jeff Toretsky is Professor of Oncology and Pediatrics at Georgetown University. He graduated with BS in Biochemistry from University of Wisconsin, Madison, WI, and recieved his MD from University of Minnesota, Minneapolis, MN. He completed fellowship training at the NCI Pediatric Branch.

Please send any questions or comments to


Tags: children · childhood cancer · sarcoma

TWiPO #17 ~ Personalized medicine: Interview with Dr Giselle Sholler

February 10th, 2014 · Comments

October 13, 2011

Host Dr. Tim Cripe and co-hosts Dr. Lars Wagner and Dr. Lionel Chow welcome guest Dr. Giselle Sholler on this episode of TWiPO. Dr. Sholler gives the background to her current research interest in neuroblastoma, and describes her nifurtimox trials and how she formed the Neuroblastoma and Medulloblastoma Translational Research Consortium (NMTRC). The physicians also discuss the specifics of the personalized medicine feasibility trial now open for neuroblastoma.

Dr. Sholler is a Pediatric Oncologist with Spectrum Health Medical Group, Helen DeVos Childrens Hospital, and directs the Pediatric Oncology Therapeutic Discovery Clinic. She is also Co-Director of the VARI/TGen Pediatric Oncology Research Program, and Associate Professor of the Neuroblastoma Translational Research Laboratory at Van Andel Research Institute. She has a faculty appointment within Michigan State University's College of Human Medicine, and continues as adjunct faculty at University of Vermont. Dr. Sholler is also a Guest Researcher in the Pediatric Oncology Branch at the NCI.


J Clin Oncol. 2010 Nov 20;28(33):4877-83. Epub 2010 Oct 4. Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers.

Science 16 Sept 2011: Vol. 333 no. 6049 pp. 1569-1571. Pushing the Envelope in Neuroblastoma Therapy

Mol Cancer Ther August 2011 10; 1311. A Pilot Clinical Study of Treatment Guided by Personalized Tumorgrafts in Patients with Advanced Cancer


Tags: children · childhood cancer · neuroblastoma

TWiPO #16 ~ Genetic Underpinnings of Ewing Sarcoma: Interview with Dr Stephen L. Lessnick

February 10th, 2014 · Comments

October 07, 2011

Dr. Tim Cripe and co-hosts Dr. Lionel Chow and Dr. Lars Wagner welcome special guest Dr. Stephen Lessnick for an in-depth discussion on the progress to date in understanding the genetics of Ewing's sarcoma. The challenges of interpreting the gene expression data as well as the ethics of collecting tumor specimens for research purposes are also explored. Dr.Stephen Lessnick is a Professor of Pediatrics and Oncological Sciences at the University of Utah, where he also serves as an Attending Physician in Pediatric Hematology/Oncology at Primary Children's Medical Center in Salt Lake City, UT. He received his PhD in Molecular Biology from UCLA in 1994, and his MD from UCLA in 1996, followed by a residency at Children's Hospital in Boston, and a fellowship at the Dana-Farber Cancer Institute and Children's Hospital. Currently, Dr. Lessnick is the Director of the Center for Children's Cancer Research at Huntsman Cancer Institute, a Jon and Karen Huntsman Presidential Professor in Cancer Research at the University of Utah, and is the Vice Chair for Biology of the Bone Tumor Committee in the Children's Oncology Group. Please send questions or comments to


Tags: children · childhood cancer · sarcoma

TWiPO #15 ~ MicroRNAs and hereditary cancer

February 10th, 2014 · Comments

September 28, 2011

Join host Dr. Tim Cripe with his co-hosts Drs. Jim Geller, Lionel Chow, and Lars Wagner in a robust discussion with special guest Dr. Kathryn Wikenheiser-Brokamp on the implications of DICER1, rare tumor registries, and difficult issues surrounding genetic counseling.

Kathryn A. Wikenheiser-Brokamp, MD, PhD, is an Associate Professor in Pathology and Pulmonary Biology at Cincinnati Children's Hospital Medical Center. Her research is focused on pediatric and adult lung diseases, including cancer. She seeks to determine the molecular mechanisms underlying Rb/p16, p53, and Dicer1 pathway function in lung development and the pathogenesis of lung disease. Dr. Wikenheiser-Brokamp holds a PhD in Developmental Biology, Developmental Biology and an MD from University of Cincinnati.

Papers discussed:

DICER1 syndrome: clarifying the diagnosis, clinical features and management implications of a pleiotropic tumour predisposition syndrome. J Med Genet. 2011 Apr;48(4):273-8.

Extending the Phenotypes Associated with DICER1 Mutations. Hum Mutat. 2011 Aug 31. doi: 10.1002/humu.21600.

Ovarian sex cord-stromal tumors, pleuropulmonary blastoma and DICER1 mutations: a report from the International Pleuropulmonary Blastoma Registry. Gynecol Oncol. 2011 Aug;122(2):246-50.

Please send questions or comments to


Tags: cancer risk · children · childhood cancer · Genetic counseling

TWiPO #14 ~ Interview with Dr Kate Matthay

February 10th, 2014 · Comments

August 24, 2011

In this enlightening interview with Dr. Kate Matthay, a reknown leader in the neuroblastoma research community, host Dr. Tim Cripe draws out the inspiration for her early interest in medicine and why her career grew with a focus on neuroblastoma. Dr. Matthay explains the history and challenges of clinical research for neuroblastoma:

10:00 challenges in planning and conducting the CCG-3891 double randomized trial questioning the need for transplant and cis-retinoic acid

15:00 discussion of the COG-A3973 trial questioning the need for purged stem cells

15:50 rationale for the COG-ANBL0532 single versus tandem transplant trial

16:13 discussion of the COG-ANBL0032 ch14.18 with cytokines trial

18:00 MIBG COG pilot trial

22:00 work with SIOP and NB protocol development for children in Morocco (N Africa)

Please send any questions or comments to


Tags: children · childhood cancer · neuroblastoma

TWiPO #13 ~ Updates, epidemiology of CNS tumors, birth order, and cell phone risks

February 10th, 2014 · Comments

August 19, 2011

Host Dr. Tim Cripe and co-hosts Dr. Lionel Chow and Dr. Jim Geller discuss updates to previous TWiPO episodes reporting on recent press coverage and publications of BiTE antibodies and modified T-cell approaches, and then discuss recent studies on birth defects, birth order, and cell phone use and possible link to risk of childhood cancers.

N Engl J Med. 2011 Aug 10. Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia.

Sci Transl Med 10 August 2011: T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia; Vol. 3, Issue 95, p. 95ra73

7:40 Decitabine upregulation of NY-ESO-1 and MAGE family expression in NB. MAGE-A1, MAGE-A3, and NY-ESO-1 can be upregulated on neuroblastoma cells to facilitate cytotoxic-T lymphocyte-mediated tumor cell killing, K Lucas

9:50 Discussion of Rosenberg paper on immunotherapy in solid tumors; Nat Rev Clin Oncol. 2011 Aug 2. doi: 10.1038/nrclinonc.2011.116. Cell transfer immunotherapy for metastatic solid cancer-what clinicians need to know. Rosenberg SA

13:00 Birth anomolies in CNS pediatric tumors

29:00 Absolute risk is small; will this lead to genome-wide association studies?

31:51 Birth order and risk of pediatric cancers

42:30 Mobile phone use and incidence of pediatric CNS tumors.

46:47 Listener question about time elapse of planning clinical trials to opening.

Please send any comments or questions to


Tags: children · childhood cancer · T-cell

TWiPO #12 ~ ALL: Anti-CD19 BiTE and Genetic Risk Groups

February 10th, 2014 · Comments

August 05, 2011

Host Dr. Tim Cripe and co-host Maureen O’Brien discuss recent papers on immunotherapy and DNA sequencing studies revealing new potential targets in acute lymphoblastic leukemia (ALL).

1:45 min. Results on use of BiTE antibody (Bi-specific T-cell engaging) blinatumomab in adults with lymphoma and leukemia:

Exp Cell Res. 2011 May 15;317(9):1255-60. Epub 2011 Mar 16. Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab

J Clin Oncol. 2011 Jun 20;29(18):2493-8. Epub 2011 May 16. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.

Use of blinatumomab in pediatrics was recently reported in Germany, and an international phase I/II trial for pediatrics is due to begin accruing this year.

Leukemia. 2011 Jan;25(1):181-4. Epub 2010 Oct 14. Complete remission after blinatumomab-induced donor T-cell activation in three pediatric patients with post-transplant relapsed acute lymphoblastic leukemia.

23:00 min. Recent findings from the TARGET Initiative (Therapeutically Applicable Research to Generate Effective Treatments)

Through NIH's TARGET initiative, scientists sequenced 120 candidate genes in 187 high-risk childhood B-precursor acute lymphoblastic leukemias (HR B-ALL) and normal tissues and combined the results with data from previous studies using microarry and gene copy number studies. Sorting through this massive amount of information revealed a high frequency of recurrent genetic alterations in several specific cancer signaling pathways. The information appears to be useful to stratify these patients into subcategories, some of whom do much better than others. These data highlight potential new therapeutic targets in certain subsets of childhood ALL.

Blood. 2010 Dec 2;116(23):4874-84. Epub 2010 Aug 10. Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome

Blood. 2011 Jun 16. [Epub ahead of print] Key pathways are frequently mutated in high risk childhood acute lymphoblastic leukemia: a report from theChildren's Oncology Group

Please send all questions or comments to


Tags: children · pediatric cancer · childhood cancer · acute lymphoblastic leukemia